In this issue:
Clinical and economic benefits of treating acute HCV
DAAs achieve high SVR rates in HCV/HIV coinfection
Novel mechanism of NK activation by HCV
Is a cure for chronic HBV infection in sight?
A novel orally bioavailable HBV viral gene expression inhibitor
Vesatolimod safe, well-tolerated in chronic HBV
Depleting nuclear cccDNA in vivo
SVR reduces risk of HCV-related extrahepatic manifestations
Ledipasvir + sofosbuvir in HCV/HBV coinfection
TNF-producing Treg cells in hepatitis A
Please login below to download this issue (PDF)